Concomitant Carcinoma In Situ Is a Feature of Aggressive Disease in Patients With Organ-Confined TCC at Radical Cystectomy

European Urology

Volumn 51, Issue 1, 2007, Pages 152-160

  Shariat, Shahrokh F ^a   Palapattu, Ganesh S ^b   Karakiewicz, Pierre I ^c   Rogers, Craig G ^b   Vazina, Amnon ^d   Bastian, Patrick J ^b   Schoenberg, Mark P ^b   Lerner, Seth P ^d   Sagalowsky, Arthur I ^a   Lotan, Yair ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bladder cancer; Carcinoma in situ; Cystectomy; Recurrence; Survival

Indexed keywords

ARTICLE; BLADDER CARCINOMA; CANCER CONTROL; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CARCINOMA IN SITU; CONTROLLED STUDY; CYSTECTOMY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PELVIS LYMPHADENECTOMY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; URETHRA CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; PROGNOSIS; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 33751407204     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.08.037     Document Type: Article

References (25)

1. Skinner D.G., Richie J.P., Cooper P.H., Waisman J., and Kaufman J.J. The clinical significance of carcinoma in situ of the bladder and its association with overt carcinoma. J Urol 112 (1974) 68-71
2. Utz D.C., Hanash K.A., and Farrow G.M. The plight of the patient with carcinoma in situ of the bladder. J Urol 103 (1970) 160-164
3. Shariat S., Palapattu G., Karakiewicz P., et al. Discrepancy between clinical and pathologic stage: impact on prognosis following radical cystectomy. Eur Urol Suppl 5 (2006) 136
4. Shariat S.F., Weizer A.Z., Green A., et al. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology 56 (2000) 735-740
5. Masood S., Sriprasad S., Palmer J.H., and Mufti G.R. T1G3 bladder cancer-indications for early cystectomy. Int Urol Nephrol 36 (2004) 41-44
6. Zincke H., Garbeff P.J., and Beahrs J.R. Upper urinary tract transitional cell cancer after radical cystectomy for bladder cancer. J Urol 131 (1984) 50-52
7. Solsona E., Iborra I., Ricos J.V., Dumont R., Casanova J.L., and Calabuig C. Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): its impact on management. Urology 49 (1997) 347-352
8. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., Huguet-Perez J., and Vicente-Rodriguez J. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J Urol 164 (2000) 1183-1187
9. Nixon R.G., Chang S.S., Lafleur B.J., Smith J.J., and Cookson M.S. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol 167 (2002) 502-505
10. Schrier B.P., Hollander M.P., van Rhijn B.W., Kiemeney L.A., and Witjes J.A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 45 (2004) 292-296
11. Knowles M.A., Elder P.A., Williamson M., Cairns J.P., Shaw M.E., and Law M.G. Allelotype of human bladder cancer. Cancer Res 54 (1994) 531-538
12. Habuchi T., Ogawa O., Kakehi Y., et al. Allelic loss of chromosome 17p in urothelial cancer: strong association with invasive phenotype. J Urol 148 (1992) 1595-1599
13. Dyrskjot L., Kruhoffer M., Thykjaer T., et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64 (2004) 4040-4048
14. Sarkis A.S., Dalbagni G., Cordon-Cardo C., et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 152 (1994) 388-392
15. Shariat S.F., Pahlavan S., Baseman A.G., et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology 57 (2001) 60-65
16. Shariat S.F., Kim J.H., Ayala G.E., Kho K., Wheeler T.M., and Lerner S.P. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol 169 (2003) 938-942
17. Shariat S.F., Kim J., Raptidis G., Ayala G.E., and Lerner S.P. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 61 (2003) 1140-1145
18. Spruck III C.H., Ohneseit P.F., Gonzalez-Zulueta M., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54 (1994) 784-788
19. Rosin M.P., Cairns P., Epstein J.I., Schoenberg M.P., and Sidransky D. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 55 (1995) 5213-5216
20. Stenzl A., Bartsch G., and Rogatsch H. The remnant urothelium after reconstructive bladder surgery. Eur Urol 41 (2002) 124-131
21. Tobisu K., Tanaka Y., Mizutani T., and Kakizoe T. Transitional cell carcinoma of the urethra in men following cystectomy for bladder cancer: multivariate analysis for risk factors. J Urol 146 (1996) 1551-1554
22. Hassan J.M., Cookson M.S., Smith Jr. J.A., Johnson D.L., and Chang S.S. Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy. J Urol 172 (2004) 882-884
23. Clark P.E., Stein J.P., Groshen S.G., et al. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol 172 (2004) 1342-1347
24. Stein J.P., Clark P., Miranda G., Cai J., Groshen S., and Skinner D.G. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol 173 (2005) 1163-1168
25. Pectasides D., Pectasides M., and Nikolaou M. Adjuvant and neoadjuvant chemotherapy in muscle-invasive bladder cancer: literature review. Eur Urol 48 (2005) 60-68